Patients with Crohn’s disease display an altered serum IgG glycosylation signature that is detectable many years before clinical diagnosis and is associated with increased levels of pathogenic anti-mannan antibodies. The altered IgG glycoforms activate innate immune cells, in a preclinical phase, promoting the transition to intestinal inflammation.